AVEO Pharmaceuticals Revenue and Competitors

Boston, MA USA

Location

$553.6M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • AVEO Pharmaceuticals's estimated annual revenue is currently $44.2M per year.(i)
  • AVEO Pharmaceuticals's estimated revenue per employee is $193,750
  • AVEO Pharmaceuticals's total funding is $553.6M.

Employee Data

  • AVEO Pharmaceuticals has 228 Employees.(i)
  • AVEO Pharmaceuticals grew their employee count by 5% last year.

AVEO Pharmaceuticals's People

NameTitleEmail/Phone
1
VP Clinical OperationsReveal Email/Phone
2
VP Program ManagementReveal Email/Phone
3
SVP MarketingReveal Email/Phone
4
VP Technical OperationsReveal Email/Phone
5
VP, Compliance & Regulatory CounselReveal Email/Phone
6
ControllerReveal Email/Phone
7
SVP, General Counsel at AVEO OncologyReveal Email/Phone
8
VP, Information TechnologyReveal Email/Phone
9
VP, FinanceReveal Email/Phone
10
VP Information TechnologyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is AVEO Pharmaceuticals?

AVEO Oncology is founded on a unique drug discovery and development approach called the Human Response Platform™. With it, we aim to translate cancer biology insights into next generation therapeutics targeted to specific patients living with cancer who will benefit most.

keywords:N/A

$553.6M

Total Funding

228

Number of Employees

$44.2M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

AVEO Pharmaceuticals News

2022-04-20 - Brokerages Anticipate AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO ...

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its...

2022-04-17 - IMV Inc. Names Michael P. Bailey Chairman of The Board

... President and Chief Executive Officer of AVEO Oncology, ... and Senior Vice President of Business Development at Synta Pharmaceuticals.

2022-04-06 - AVEO Pharmaceuticals, Inc. (AVEO) Stock Is Lower By -7.56% This Week: Buy, Hold, or Sell?

AVEO Pharmaceuticals, Inc. (AVEO) stock has fallen -12.84% over the last 12 months, and the average rating from Wall Street analysts is a...

2019-01-31 - FDA stiff-arms Aveo on ti­vo, again; Sunovion Parkin­son's drug re­ject­ed

→ Aveo On­col­o­gy was hit with a fresh set­back on Thurs­day. Its 2013-re­ject­ed tivozanib is still not ready for a new mar­ket­ing ap­pli­ca­tion, the com­pa­ny said, cit­ing FDA feed­back. The agency rec­om­mend­ed that the drug de­vel­op­er not sub­mit the ap­pli­ca­tion as pre­lim­i­nary o ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$34.3M2282%$23.6M
#2
$7.5M229-5%N/A
#3
$51.1M230-5%N/A
#4
$34.6M2306%$71.5M
#5
$36M2312%$114.5M